The company, which raised $460 million in an IPO in July, has developed a pipeline of selective agents, two of which have advanced to Phase I clinical trials.
The firm also aims to commercialize a new version of its PraediCare Dx platform, which will directly detect heterodimer protein complexes on a tumor cell's surface.
Thrive Earlier Detection is banking on targeted detection of frequent cancer mutations, coupled with protein markers, while competitors turn to genome-wide approaches.
